Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis

Naiara Santana-Codina, Anjali A. Roeth, Yi Zhang, Annan Yang, Oksana Mashadova, John M. Asara, Xiaoxu Wang, Roderick T. Bronson, Costas A. Lyssiotis, Haoqiang Ying & Alec C. Kimmelman

Oncogenic KRAS is the key driver of pancreatic ductal adenocarcinoma (PDAC). We previously described a role for KRAS in PDAC tumor maintenance through rewiring of cellular metabolism to support proliferation. Understanding the details of this metabolic reprogramming in human PDAC may provide novel therapeutic opportunities. Here we show that the dependence on oncogenic KRAS correlates with specific metabolic profiles that involve maintenance of nucleotide pools as key mediators of KRAS-dependence. KRAS promotes these effects by activating a MAPK-dependent signaling pathway leading to MYC upregulation and transcription of the non-oxidative pentose phosphate pathway (PPP) gene RPIA, which results in nucleotide biosynthesis. The use of MEK inhibitors recapitulates the KRAS-dependence pattern and the expected metabolic changes. Antagonizing the PPP or pyrimidine biosynthesis inhibits the growth of KRAS-resistant cells. Together, these data reveal differential metabolic rewiring between KRAS-resistant and sensitive cells, and demonstrate that targeting nucleotide metabolism can overcome resistance to KRAS/MEK inhibition.

DOI: 10.1038/s41467-018-07472-8

1 Division of Genomic Stability and DNA Repair, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. 2 Department of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, Aachen 52074, Germany. 3 Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA. 4 Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115, USA. 5 Rodent Histopathology Core, Harvard Medical School, Boston 02115 MA, USA. 6 Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA. 7 Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA. 8 Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. 9 Department of Radiation Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA. Correspondence and requests for materials should be addressed to A.C.K. (email: Alec.Kimmelman@NYUMC.org)
Pancreatic ductal adenocarcinoma (PDAC) is estimated to become the second cause of cancer-related death by 2020, with an expected 5-year survival rate of ~8%. This poor prognosis is a consequence of late stage diagnosis, which limits surgical intervention, as well as resistance to conventional treatments such as chemotherapy and radiation. The genetic events that drive pancreatic intraepithelial neoplasia (PanIN) formation and progression to PDAC are well known and have been validated in multiple mouse models. These involve mutations in tumor suppressor genes like CDKN2A (that encodes INK4A or ARF), TP53 and SMAD4, as well as activation of the KRAS oncogene. Despite the knowledge of the PDAC genetic signature, therapeutic efforts to inhibit the key oncogenic driver, KRAS, have been largely unsuccessful.

To facilitate survival and proliferation, tumor cells rewire their metabolism to maintain redox homeostasis and fuel anabolic pathways. Indeed, work from our lab has shown a critical role for a novel glutamine-dependent pathway in the maintenance of redox balance and tumor growth in PDAC. In addition, we and others have reported on the engagement of metabolic recycling and scavenging pathways in pancreatic cancer, which enable biosynthetic activity in a nutrient poor microenvironment. Beyond extracellular scavenging, pancreatic cancer cells also engage metabolically with other cells in the tumor microenvironment. For example, we have recently described a model underlining the importance of the microenvironment and its contribution to tumor metabolism in which pancreatic stellate cells secrete alanine that can be taken up by PDAC cells to fuel several catabolic and anabolic processes.

Growing evidence supports that activation of several oncogenes such as KRAS and MYC can induce metabolic reprogramming and this opens the possibility of new therapeutic strategies, targeting the deregulated metabolism in cancer. We previously generated an inducible KrasG12D (iKras) genetically engineered mouse model (GEMM), with which we revealed an essential role of Kras in tumor maintenance in vivo, and this functioned in part through the reprogramming of metabolism. Kras promoted an increase in glucose uptake, shunting glucose intermediates into the hexosamine biosynthesis pathway (HBP) and the non-oxidative pentose phosphate pathway (PPP). This shift decoupled redox control from ribose synthesis, with redox regulated by malic enzyme 1 (ME1). The KRAS-driven metabolic changes were mediated by the RAF/MEK/ERK pathway, which results in upregulation of MYC and the transcriptional regulation of rate-limiting enzymes in glucose metabolism.

This study drew attention to several potential therapeutic strategies, either by directly targeting MEK or the metabolic pathways over-activated in a mutant KRAS context. However, there were several aspects that remained to be defined. While it has become clear that tumors may have varying degrees of reliance on oncogenic KRAS, it will be critical to understand how KRAS-dependence impacts metabolic rewiring and the associated vulnerabilities. Additionally, the context-specific dependence on KRAS-driven metabolic pathways remains to be determined. Here, we have characterized the differential metabolic profiles of KRAS-resistant and sensitive human PDAC cell lines and identified metabolic susceptibilities of KRAS-resistant cells. Additionally, we have shown that KRAS dependency is in large part due to its role in nucleotide biosynthesis. Overall, this work describes a mechanism by which KRAS mediates tumor survival and metabolic reprogramming in human PDAC and highlights potential therapeutic targets in the nucleotide biosynthesis pathway to overcome KRAS/MEK inhibitor resistance.

Results
Kras dependency correlates with differential metabolic rewiring. It has been previously reported that mutant KRAS cell lines could be classified as KRAS-dependent and independent based on their sensitivity to KRAS knockdown. To investigate the role of KRAS in metabolic reprogramming, we initially interrogated a panel of human PDAC cell lines for differential sensitivity to KRAS depletion. We downregulated KRAS in PDAC cells using two lentiviral short hairpin RNAs (shRNAs) and we measured their ability to grow and form colonies in clonogenic assays. KRAS ablation impacted growth and clonogenic growth of all cell lines tested, but some cell lines (referred as KRAS-resistant) were still able to form colonies independent of KRAS expression (Supplementary Fig. 1a). Although KRAS inhibition decreased proliferation in all cell lines (Supplementary Fig. 1b), no induction of cell death was observed in KRAS-resistant lines (Fig. 1a). In contrast, KRAS depletion induced significant cell death in KRAS-sensitive cell lines (Fig. 1a).

We previously described that Kras activation in a PDAC GEMM orchestrates a metabolic program that consists in increased flux through glycolysis, non-oxidative PPP and HBP (Fig. 1b) through transcriptional control of key enzymes in these pathways. To evaluate the metabolic profile in the set of human KRAS-resistant and sensitive cells, we performed targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) after KRAS depletion. Consistent with the role of KRAS in regulating glycolysis, our metabolomic studies showed a decrease in several glycolytic intermediates including fructose bisphosphate (FBP), glyceraldehyde-3-phosphate (Ga3P) and dihydroxyacetone-phosphate (DHAP) in nearly all cell lines after KRAS extinction (Fig. 1c). To confirm the general decrease in glycolysis after KRAS inactivation, we measured the extracellular media acidification rate (ECAR) (Fig. 1d). KRAS depletion decreased ECAR in all cell lines consistent with the metabolomics data. These metabolic changes correlated with reduced expression of rate-limiting glycolytic genes (HK1, HK2) (Supplementary Fig. 1c). This is in agreement with the iKras GEMM suggesting that KRAS controls glucose metabolism in the majority of human PDAC cells by regulating the expression of glycolytic enzymes. Consistent with our initial findings, metabolites in the HBP (Supplementary Fig. 1d) were not differentially regulated in resistant vs. sensitive cells, suggesting that KRAS broadly supports both glycolysis and HBP.

The iKras GEMM highlighted the importance of incorporating glucose into the non-oxidative PPP for ribose and nucleotide biosynthesis. Supporting this idea, KRAS extinction decreased pentose phosphate in all cell lines, but significantly more in sensitive cells (Fig. 1e). Consistent with the reduction in PPP intermediates, pyrimidine nucleotides like UDP and UTP dropped in all cell lines after shKras, but more significantly in sensitive cells (Fig. 1e). These results suggest a differential response to KRAS depletion in resistant vs. sensitive cells in the regulation of the PPP and nucleotide biosynthesis.

To confirm the importance of nucleotide metabolism, cell death was assessed in KRAS-depleted sensitive cells cultured in media supplemented with ribo and deoxyribonucleosides (Supplementary Fig. 1e). This combination of nucleosides was able to rescue cell death upon KRAS knockdown (Supplementary Fig. 1e). Furthermore, the addition of uridine, essential for synthesis of pyrimidines, and inosine, important for purine synthesis and salvage pathways, were also able to suppress cell death (Fig. 1f, Supplementary Fig. 1f–g). Interestingly, the ability of KRAS to support cell proliferation was not impacted by the addition of nucleosides indicating that other aspects of KRAS function are required for proliferation (Supplementary Fig. 1h). Together these data indicate that KRAS extinction induces a differential
reduction in nucleotide synthesis in sensitive and resistant cells that leads to cell death in KRAS-addicted cell lines, and restoring nucleotide pools via supplementation can rescue survival. In a similar manner, iKras mouse PDAC cell lines derived from tumors that developed resistance to doxycycline-mediated loss of KrasG12D (escaper tumor lines, iKras−) displayed decreased glycolysis as shown by decreased glucose uptake/lactate excretion (Supplementary Fig. 2a). These lines are compared to iKras mouse PDAC cell lines derived from tumors that developed resistance to doxycycline-mediated KrasG12D control but were still dependent on Kras signaling (iKras+). Furthermore, the iKras− lines also showed a drop in glycolytic intermediates including DHAP, 3PG, G3P and PEP (Supplementary Fig. 2b) in steady state levels, and this was validated using 13C-labeled carbon tracing (Supplementary Fig. 2c). In contrast to the human knockdown studies, iKras− and iKras+ cells had similar PPP metabolite levels, which may reflect an adaption to Kras independence (Supplementary Fig. 2d−e). To determine PPP activity, we calculated the flux of glucose carbon into RNA and found that Kras-dependent murine PDA lines (iKras+) exhibited, proportionally, a much greater utilization of the non-oxidative PPP (Supplementary Fig. 2f). These results further corroborate the correlation between Kras dependence and non-oxidative PPP utilization.

The MAPK-MYC-RPIA pathway mediates KRAS resistance. KRAS exerts its effects by activation of several canonical downstream pathways. Several studies have identified the MAPK pathway as the main mediator of KRAS tumorigenic effects in PDAC. In agreement with this, we confirmed that KRAS depletion decreased Erk phosphorylation (Thr202/Tyr204) (Fig. 2a) with a minor impact on pAkt (Ser473)/Akt levels (Supplementary Fig. 3a). Indeed, MEK inhibition correlated with the KRAS dependence pattern, with KRAS-resistant cells showing the highest IC50 both for AZD8330 (Fig. 2b), as well as a second

**Fig. 1** KRAS inhibition induces differential metabolic rewiring in PDAC cells. a KRAS inhibition impacts viability differentially after 48 h in complete media, as shown by trypan-blue exclusion assay. Error bars represent s.e.m. of 3 independent experiments. b Scheme representing the main enzymes and metabolites in the glycolytic and the pentose phosphate pathway (PPP). c Fold change of glycolytic intermediates after KRAS inhibition, each shRNA relative to its corresponding shGFP. Error bars represent s.d. of n = 3 technical replicates from independently prepared samples from individual wells. Significance determined for each shRNA vs. shGFP. G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; FBP, fructose 1,6-bisphosphate; Ga3P, glyceraldehyde 3-phosphate; DHAP, dihydroxyacetone phosphate. d Extracellular acidification rate (ECAR) is decreased after KRAS depletion. All values normalized to cell number determined with crystal violet staining and fold change normalized to Panc-1 shGFP. Error bars represent s.e.m. of 4 independent experiments (‘ shows comparison to each cell line’s shGFP, # shows comparison to Panc-1 shGFP). e Fold change of PPP intermediates and pyrimidines after KRAS inhibition, each shRNA normalized to its corresponding shGFP. Error bars represent s.d. of n = 3 technical replicates from independently prepared samples from individual wells. Significance determined for each shRNA vs. shGFP. Pentose-P, Pentose-phosphate; UDP, uridine diphosphate; UTP, uridine triphosphate. f Cell death analyzed by flow cytometry after KRAS depletion in Tu8902 cells in media supplemented with U (uridine) and I (inosine) at 1 mM, respectively. Bars represent relative cell death vs. shGFP (error bars show s.e.m. of 5 independent experiments). For all panels, significance determined with t-test. *p < 0.05, **p < 0.01, ***p < 0.001
MEK inhibitor, trametinib (Supplementary Fig. 3b–c). Further analysis of downstream mediators after KRAS depletion, revealed a downregulation of Myc levels mainly in sensitive cells, at the RNA and protein levels (Fig. 2a–c). We had shown previously that RPIA is a MYC-regulated gene downstream of oncogenic KRAS, in the non-oxidative PPP 19,24, essential for ribose biosynthesis 25 and crucial mediator of PDAC tumorigenesis in mice 19. Given the differences in nucleotide metabolism in resistant and sensitive cells, we investigated RPIA levels after KRAS extinction. KRAS inhibition reduced RPIA expression in all sensitive cell lines, but had minimal impact in the resistant lines (Fig. 2a–c). These results suggest that resistance to KRAS extension.
inhibition may be mediated by convergent mechanisms that ultimately lead to maintenance of RPIA expression in order to maintain nucleotide pools. Similar results were obtained with MEK inhibition, showing minimal changes in RPIA expression in the resistant lines both with AZD5830 (Fig. 2d, e) and trametinib (Supplementary Fig. 3e, f). Interestingly, we discovered a subset of resistant cell lines that are able to maintain RPIA expression despite decreasing MYC levels, further reinforcing the role of RPIA in mediating KRAS resistance (Fig. 2d, e).

While MEK inhibition exhibited similar effects as Kras knockdown in many regards, a clear distinction was that MEK inhibition induced cytostasis instead of cell death (Supplementary Fig. 3d). As previously reported, MEK inhibition induced compensatory activation of the PI3K pathway as evidenced by AKT activation (Supplementary Fig. 3g) in sensitive lines. In contrast, KRAS knockdown in sensitive lines did not result in compensatory AKT activation (Supplementary Fig. 3a). We therefore speculated that activation of the PI3K pathway in the setting of MEK inhibitor treatment could explain the differential cytostatic effect observed with MEK inhibition compared to the shKRAS. Consistent with this, concurrent inhibition of AKT and MEK increased cell death in sensitive cells (Supplementary Fig. 3h).

To further understand the role of the MEK-MYC-RPIA axis in KRAS/MEK dependency, we generated two resistant clones of the MiaPaCa2 cell line that were able to grow and form colonies in the presence of AZD8330 (Fig. 2f, g). In contrast to the parental line, the newly generated resistant cells sustained MYC and RPIA levels after MEK inhibition (Fig. 2h, i), while HK2 expression was not recovered (Fig. 2i). Together these data suggest that expression of MYC and RPIA mediate resistance to MEK inhibitors and that resistance is not likely due to a global reactivation of KRAS-dependent metabolism.

Also in agreement with the shKras-induced metabolic changes, MEK inhibition for 72 h decreased glycolysis, seen as a drop in glycolytic metabolites in resistant and sensitive cells (Fig. 3a), as well as ECAR (Fig. 3b) more prominently in sensitive cells. MEK inhibition decreased nucleotide synthesis (purine and pyrimidines) in sensitive and resistant lines at 72 h (Fig. 3c) but more profoundly in sensitive cells. These differences were enhanced when cells were treated with a MEK inhibitor for 24 h in lower glucose/glutamine conditions, showing a significant decrease in glycolysis (Supplementary Fig. 4a), PPP (Supplementary Fig. 4b) and purines/pyrimidines (Supplementary Fig. 4c) only in sensitive cells. The decrease in nucleotide biosynthesis was confirmed by N15-Glutamine tracing studies, which showed a trend towards lower incorporation in sensitive cell lines as compared to resistant for pyrimidines (Supplementary Fig. 4d) and more significantly purines (Fig. 3d) upon MEK inhibition. This pattern correlated with selective drop in glycolytic and PPP gene expression after AZD8330 (Supplementary Fig. 4e) and trametinib (Supplementary Fig. 3f) treatment in sensitive lines. Finally, mitochondrial metabolism was also differentially impacted in sensitive cells, as shown by decrease in TCA cycle/redundy intermediates (Fig. 3e, Supplementary Fig. 4f), respiration (Supplementary Fig. 4g), and GSH/GSSG ratio (Supplementary Fig. 4h).

Finally, to confirm the role of MYC as a mediator of KRAS resistance, we suppressed MYC expression using RNAi. MYC depletion decreased the survival and proliferation of all cell lines (Fig. 4a, b, Supplementary Fig. 5a–b) but it had a cytostatic effect in non-transformed cell lines (Supplementary Fig. 5a, c), confirming its essential role in PDAC survival. MYC ablation reduced RPIA levels in resistant and sensitive cells, both at the RNA (Fig. 4c) and protein levels (Fig. 4d). Together these data suggest that expression of MYC and RPIA mediates resistance to MEK inhibitors.

RPIA inhibition sensitizes KRAS-resistant cells. Given the limited pharmacological strategies available to inhibit KRAS and the resistance we observed to MEK inhibitors, targeting of downstream metabolic pathways may be an attractive strategy to inhibit PDAC growth, particularly in tumors that have de novo or acquired resistance to MEK or KRAS inhibition. Our results highlighted a pathway downstream of KRAS, leading to RPIA expression that was critical for mediating resistance to MEK inhibition. RPIA depletion reduced growth and clonogenic survival of both resistant and sensitive cell lines (Fig. 5a, Supplementary Fig. 5d) proving that the PPP is an essential pathway to maintain PDAC growth. RPIA deletion induced cell death in most of the cell lines tested (Fig. 5b, Supplementary Figure 5e) although to a lesser extent than Kras deletion. On the other hand, RPIA deletion didn’t induce cell death (Supplementary Fig. 5c) or impair growth (Supplementary Fig. 5d) in non-transformed cell lines (IMR-90 and hPSC), indicating there might be an optimal therapeutic window for treating PDAC with RPIA inhibition. Interestingly, one of the KRAS-resistant lines (8988 T) was more resistant to RPIA inhibition (Fig. 5a, Supplementary Fig. 5d) than other lines, suggesting that other compensatory mechanisms might be acting in this particular cell line. CRISPR deletion of RPIA (Supplementary Fig. 5f) produced similar data to the shRNA studies (Supplementary Fig. 5g).

Consistent with the importance of nucleotide metabolism in this phenotype, cell death induced by RPIA downregulation was attenuated when shRPIA cells were cultured in a media supplemented with nucleosides (Fig. 5b, c). Additionally, supplementation of Uridine and Inosine alone or in combination, was also able to rescue cell death (Fig. 5d). Nucleotides were also able to partially recover colony formation in a KRAS-sensitive
and resistant cell line after RPIA CRISPR KO (Supplementary Fig. 5h) or shRPIA (Supplementary Fig. 5i). The rescue of the RPIA depletion with nucleotides was more pronounced than that seen in rescuing shKras cells, further highlighting the broader functions of oncogenic KRAS. Finally, overexpression of a mouse RPIA cDNA was able to rescue cell death in shRPIA cells (Fig. 5e, Supplementary Figure 5j), confirming an on-target inhibition of the protein. Together, these data reinforce the importance of the non-oxidative PPP in maintaining nucleotide pools and survival in PDAC cells. Also, it highlights RPIA as an attractive therapeutic target in PDAC tumors that are resistant to MEK inhibitors.

**Inhibiting pyrimidine synthesis as a strategy to target PDAC**. Our metabolomic studies showed a differential decrease in nucleotides after KRAS depletion (Fig. 1e) and MEK inhibition (Supplementary Fig. 4c) between sensitive and resistant cells, suggesting that pyrimidine synthesis might be a therapeutic target in PDAC.

---

**Fig. 3** MEK inhibitor-induced metabolic reprogramming is comparable to shKras. **a** For all metabolomics experiments in this figure, cells were treated with AZD8330 (50 nM) for 72 h in media containing glucose 25 mM and glutamine 4 mM. Values are represented as fold change vs. DMSO-treated cells for glycolysis, PPP and HBP metabolites. Error bars represent s.d. of n = 3 technical replicates from independently prepared samples from individual wells. Significance determined for each cell line treated with AZD8330 vs. vehicle. **b** Quantification of Extracellular Acidification Rate (ECAR) normalized to cell number determined by crystal violet staining. All values relative to Panc-1 DMSO, error bars ± s.e.m. of independent experiments (‘’ shows comparison to each cell line’s control (DMSO)). # shows comparison to Panc1-DMSO. **c** Fold change of metabolites in the pyrimidine and purine pathways after AZD8330 treatment. UMP, uridine monophosphate; CDP, cytidine diphosphate; CTP, cytidine triphosphate; dCTP, deoxy CTP; dTTP, deoxy thymidine triphosphate; IMP, inosine monophosphate; AMP, adenosine monophosphate; dATP, deoxy adenosine triphosphate; GDP, guanosine diphosphate. Significance determined for each cell line treated with AZD8330 vs. vehicle. **d** Tracing experiments in Panc-1 and Tu8902 cells treated with AZD8330 (50 nM) in medium containing stable isotope-labeled glutamine (Amide-15N) for 24 h to label incorporation into the purine ring. Bars show fractional labeling vs. unlabeled pool, error bars indicate ± s.d. of n = 3 technical replicates from independently prepared samples from individual wells. **e** Fold change of metabolites in the tricarboxylic acid (TCA) cycle, transaminase and redox pathways after AZD8330 treatment, error bars indicate ± s.d. of n = 3 technical replicates from independently prepared samples from individual wells. Significance determined for each cell line treated with AZD8330 vs. vehicle. Ala, alanine; SAHomoCys, S-adenosyl-L-homocysteine; GSH, reduced glutathione; GSSG, oxidized glutathione. For all panels, significance determined with t-test. ‘*’ p < 0.05, ‘**’ p < 0.01, ‘***’ p < 0.001

---

6 NATURE COMMUNICATIONS | (2018) 9:4945 | DOI: 10.1038/s41467-018-07472-8 | www.nature.com/naturecommunications
suggesting that inhibition of other nucleotide biosynthetic pathways could sensitize resistant cells in a similar fashion as PPP blockade.

While RPIA may be a potential therapeutic target, there are currently no available inhibitors. DHODH is an enzyme in the pyrimidine biosynthesis pathway that enables the conversion of dihydroorotate to orotate. Although nucleotide biosynthetic processes take place in the cytoplasm, DHODH is located in the inner mitochondrial membrane, where it associates with complex II and III of the electron transport chain and participates in ubiquinone reduction. Therefore, DHODH inhibition could dually target respiration and nucleotide synthesis, two of the important pathways that appear necessary in PDAC.

In order to investigate the potential role of DHODH inhibition in PDAC growth, DHODH was depleted in our panel of PDAC cell lines using shRNAs. DHODH inhibition (Supplementary Fig. 6a) decreased growth and clonogenic survival of both resistant and sensitive cells (Fig. 6a, Supplementary Fig. 6b) with only minor effects in non-transformed cells (Supplementary Fig. 6c, d). These effects were reproduced with brequinar (Fig. 6b) and lefunomide (Supplementary Fig. 6e), two pharmacological inhibitors of DHODH. Furthermore, lefunomide also was effective in inhibiting growth of the two MiaPaCa2 MEKi-resistant cell lines (Fig. 6c). Additionally knockdown of DHODH, as well as RPIA inhibited 3D growth of PDAC spheroids (Supplementary Figure 6f).

To assess the metabolic effects of DHODH inhibition, we performed metabolomic studies in cells (Fig. 6d) treated with lefunomide. Lefunomide efficiently blocked DHODH activity, leading to an accumulation of upstream intermediates like dihydroorotate, N-carbamoyl aspartate, carbamoyl phosphate and aspartate, and a drop in downstream metabolites like orotate, uridine-derived nucleotides (UMP, UDP, UTP) and other pyrimidines (CTP, dTTP). DHODH inhibition did not decrease purines (Fig. 6d) but had significant effects on pyrimidine biosynthesis (Fig. 6d). There were also decreases in some upper glycolytic intermediates with DHODH inhibition (Supplementary Fig. 6g). Metabolomic analysis of shDHODH cells also confirmed the block in pyrimidine synthesis (Fig. 6e) but this was accompanied by decreases in purines (Fig. 6e) and glycolytic intermediates (Supplementary Fig. 6h), suggesting potential adaptive responses to a broader long-term effect of DHODH depletion seen with shRNAs as compared to acute pharmacological inhibition. Additionally, genetic ablation of DHODH, a key structural component in the ETC, would have potential scaffold effects not seen with pharmacologic inhibitors.

DHODH inhibition has been shown to decrease mitochondrial membrane potential and increase ROS. To test the consequences of DHODH inhibition on mitochondrial metabolism, we measured OCR after lefunomide treatment. Lefunomide efficiently blocked basal and maximal respiration in both resistant and sensitive cell lines after 16 h of treatment (Fig. 6f). These differences were less evident when cells were incubated at shorter timepoints (1, 3, 6 h), suggesting that lefunomide’s effect on OCR was a consequence of several aspects including impaired pyrimidine synthesis and direct mitochondrial function (Supplementary Fig. 6i). Consistent with the lower levels of respiration after DHODH inhibition, several metabolites in the TCA cycle were also decreased after lefunomide treatment (Supplementary Fig. 6g) and shDHODH expression (Supplementary Fig. 6h).

Also, in agreement with DHODH’s role in maintaining redox balance, the GSH/GSSG ratio dropped after lefunomide treatment (Supplementary Fig. 6i) and DHODH depletion (Supplementary Fig. 6k). Finally, we assessed the potential
anti-tumor effects of DHODH inhibition in a PDAC tumor model. Leflunomide has been previously tested in vivo, resulting in weight loss and lethargy and was poorly tolerated\textsuperscript{32}. Therefore, we used brequinar (BQ), a more potent and specific inhibitor of DHODH which has shown efficacy in an AML model\textsuperscript{32}. BQ was dosed once every other day, a pattern that showed minimal toxicity in mice (Supplementary Fig. 7a), with no signs of anemia (Supplementary Fig. 7b) or splenomegaly (Supplementary Fig. 7c). To test the efficacy of DHODH inhibition by BQ in vivo, we performed metabolomics of pancreata of treated mice (50 mg/kg, each) and cell death was assessed by trypan blue exclusion. Error bars represent s.e.m of 3 independent experiments (* shows comparison to shGFP, # shows comparison to shRPIA in MEM). d Cell death analyzed by flow cytometry after RPIA depletion in MiaPaCa2 cells in media supplemented with U (uridine) and I (inosine) alone or in combination (1 mM, respectively). Bars represent relative fold change in cell death vs. shGFP of 4 averaged independent experiments (error bars show s.e.m). e Cell death analyzed by flow cytometry after RPIA depletion and mRPIA expression in MiaPaCa2 cells. Bars represent increase in cell death as compared to shGFP (error bars show s.e.m of 4 independent experiments). For all panels, significance determined with t-test. *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 7) in BQ-treated mice, suggesting BQ treatment might also impact the tumor microenvironment. Additionally, our data showed no recovery in the pyrimidine pools after BQ treatment along with a slower proliferation rate, which suggests the residual nucleotide pools might be enough to sustain a residual reduced proliferation rate.

**Discussion**

Here, we describe a metabolic reprogramming that maintains nucleotide biosynthesis to support resistance to KRAS or MEK inhibition. In fact, targeting the PPP via RPIA depletion or inhibiting pyrimidine biosynthesis directly through DHODH shows activity in all human PDAC cell lines tested. We propose
that targeting ribose or pyrimidine synthesis is an attractive therapeutic strategy even in tumors that have developed resistance to KRAS/MEK inhibition.

These studies also inform us regarding the metabolic heterogeneity of human PDAC tumors. In agreement with the iKras mouse model which is a highly Kras-dependent tumor, we have confirmed that KRAS acts mainly through the MAPK pathway to support metabolism and growth. However, unlike the iKras GEMM, KRAS/MEKi-resistant cells are able to sustain MYC and/or RPIA expression downstream of MEK in order to maintain nucleotide synthesis. This becomes clear in the subset of immediately KRAS-resistant cell lines originally classified as slow proliferating, which downregulate MYC, but still maintain RPIA expression. Suppression of MYC or RPIA mediates cell death in most resistant and sensitive cell lines.

Our metabolomic studies suggest that either suppressing KRAS expression or inhibiting MEK/MAPK pharmacologically depletes nucleotides to a greater degree in sensitive lines than in resistant ones. Not unexpectedly, there are some differences between genetic inhibition of KRAS as compared to pharmacologic inhibition of MEK. These are likely a consequence of the fact that KRAS has multiple other effects in addition to MEK/MAPK activation, as well as to compensatory activation of additional signaling pathways in response to MEK inhibition, such as PI3K. The common metabolic feature both in human and mouse KRAS/MEK resistant cells is their ability to maintain nucleotide synthesis, which is important to maintain survival. This mechanism has been recently proven to be crucial in mediating resistance to other drugs like gemcitabine. RPIA is an enzyme that catalyzes the conversion between ribose-5-phosphate and ribulose-5-phosphate and it has been implicated in hepatocarcinogenesis. RPIA deletion in our model impacts purine/pyrimidine synthesis, leading to cell death and overcoming the resistance mechanism described previously.

Unfortunately, there are only a few available PPP inhibitors targeting genes in the oxidative arm (6-aminonicotinamide) or the non-oxidative arm (oxymethione, TKT) and these lack potency and specificity. Given the dynamic nature of the non-ox PPP and its interwining with glycolysis, it may be more prone to compensatory effects. Therefore, inhibition of enzymes further downstream in the pathway could result in more potent anti-tumor effects. DHODH is a particularly attractive target in the pyrimidine pathway and its mitochondrial location has proven to be important in mediating conversion of DHO to orotate together with reduction of ubiquinone to ubiquinol. Therefore, DHODH couples nucleotide synthesis to respiration, targeting two of the pathways that are critical in PDAC. DHODH’s expression or activity is increased in several cancers and in the last few years there has been growing interest about its potential as therapeutic target in cancers such as AML, BRAF mutant melanoma, triple negative breast cancers and PTEN mutant tumors. Leflunomide is an FDA-approved drug used in the clinic to treat rheumatoid arthritis and is a weak and non-specific DHODH inhibitor. However, it has proven to be toxic in vivo at doses needed to inhibit DHODH. On the other hand, Brequinar is a more potent and specific inhibitor of DHODH with proven efficacy when dosed in an intermittent pattern that allows periods of nucleotide depletion in a model of leukemia. Brequinar’s effects in vitro were more potent than leflunomide and it showed activity as a monotherapy in a xenograft model of human PDAC. Despite initial activity and even some complete responses, tumors ultimately progressed at a slower but sustained rate with BQ treatment. We showed that BQ-treated tumors didn’t upregulate other metabolic pathways and showed lower activation of proliferating markers. It remains to be evaluated the relevance of the effects observed on the tumor microenvironment, as well as developing effective combinatory therapeutic strategies. Furthermore, DHODH and RPIA inhibition was well tolerated in non transformed cells, suggesting that these pathways may have potential for therapeutic inhibition although more in vivo studies should be performed to conclusively determine this.

Overall, our work describes a differential metabolic rewiring in KRAS-resistant and sensitive cells, which is regulated by the MAPK-MYC-RPIA pathway. We identified nucleotide metabolism as a key mediator of KRAS resistance and we propose targeting enzymes in the PPP or the pyrimidine biosynthesis pathway to overcome resistance to MEK inhibitors and ultimately to future KRAS inhibitors that are in various stages of development.

Methods

Cell culture. Cell lines were obtained from ATCC and DSMZ. Establishment and growth conditions of immortalized HPDE cells were described elsewhere as well as IHC. Cells were grown in MEM (Life Technologies 11965) or IMDM (CFPAC, ThermoFisher 12440053) with 10% FBS and 1% Pen/Strep (Life Technologies 15140). Mycoplasma was routinely tested by PCR. PDAC cell lines were maintained in a centralized bank and authenticated by assessment of cell morphology as well as STR fingerprinting. Mpan96 was used as an additional KRAS/MEK sensitive cell line based on prior literature. Subsequently, it was determined that this line is the same as ASPC1. We have verified this via STR fingerprinting. As we originally received the line as Mpan96, we elected to use this nomenclature when describing the line.

MiaPaCa2 clones resistant to AZD8330 were generated by two different methods: MiaPaCa2-R2 was cultured in 50 nM while MiaPaCa2-R2 was cultured immediately in 50 nM. 50 nM is needed to inhibit DHODH. On the other hand, Brequinar is a more potent and specific inhibitor of DHODH with proven efficacy when dosed in an intermittent pattern that allows periods of nucleotide depletion in a model of leukemia. Brequinar’s effects in vitro were more potent than leflunomide and it showed activity as a monotherapy in a xenograft model of human PDAC. Despite initial activity and even some complete responses, tumors ultimately progressed at a slower but sustained rate with BQ treatment. We showed that BQ-treated tumors didn’t upregulate other metabolic pathways and showed lower activation of proliferating markers. It remains to be evaluated the relevance of the effects observed on the tumor microenvironment, as well as developing effective combinatory therapeutic strategies. Furthermore, DHODH and RPIA inhibition was well tolerated in non transformed cells, suggesting that these pathways may have potential for therapeutic inhibition although more in vivo studies should be performed to conclusively determine this.

Overall, our work describes a differential metabolic rewiring in KRAS-resistant and sensitive cells, which is regulated by the MAPK-MYC-RPIA pathway. We identified nucleotide metabolism as a key mediator of KRAS resistance and we propose targeting enzymes in the PPP or the pyrimidine biosynthesis pathway to overcome resistance to MEK inhibitors and ultimately to future KRAS inhibitors that are in various stages of development.

Methods

Cell culture. Cell lines were obtained from ATCC and DSMZ. Establishment and growth conditions of immortalized HPDE cells were described elsewhere as well as IHC. Cells were grown in MEM (Life Technologies 11965) or IMDM (CFPAC, ThermoFisher 12440053) with 10% FBS and 1% Pen/Strep (Life Technologies 15140). Mycoplasma was routinely tested by PCR. PDAC cell lines were maintained in a centralized bank and authenticated by assessment of cell morphology as well as STR fingerprinting. Mpan96 was used as an additional KRAS/MEK sensitive cell line based on prior literature. Subsequently, it was determined that this line is the same as ASPC1. We have verified this via STR fingerprinting. As we originally received the line as Mpan96, we elected to use this nomenclature when describing the line.

MiaPaCa2 clones resistant to AZD8330 were generated by two different methods: MiaPaCa2-R2 was cultured in 50 nM while MiaPaCa2-R2 was cultured immediately in 50 nM. 50 nM is needed to inhibit DHODH. On the other hand, Brequinar is a more potent and specific inhibitor of DHODH with proven efficacy when dosed in an intermittent pattern that allows periods of nucleotide depletion in a model of leukemia. Brequinar’s effects in vitro were more potent than leflunomide and it showed activity as a monotherapy in a xenograft model of human PDAC. Despite initial activity and even some complete responses, tumors ultimately progressed at a slower but sustained rate with BQ treatment. We showed that BQ-treated tumors didn’t upregulate other metabolic pathways and showed lower activation of proliferating markers. It remains to be evaluated the relevance of the effects observed on the tumor microenvironment, as well as developing effective combinatory therapeutic strategies. Furthermore, DHODH and RPIA inhibition was well tolerated in non transformed cells, suggesting that these pathways may have potential for therapeutic inhibition although more in vivo studies should be performed to conclusively determine this.

Overall, our work describes a differential metabolic rewiring in KRAS-resistant and sensitive cells, which is regulated by the MAPK-MYC-RPIA pathway. We identified nucleotide metabolism as a key mediator of KRAS resistance and we propose targeting enzymes in the PPP or the pyrimidine biosynthesis pathway to overcome resistance to MEK inhibitors and ultimately to future KRAS inhibitors that are in various stages of development.

Methods

Cell culture. Cell lines were obtained from ATCC and DSMZ. Establishment and growth conditions of immortalized HPDE cells were described elsewhere as well as IHC. Cells were grown in MEM (Life Technologies 11965) or IMDM (CFPAC, ThermoFisher 12440053) with 10% FBS and 1% Pen/Strep (Life Technologies 15140). Mycoplasma was routinely tested by PCR. PDAC cell lines were maintained in a centralized bank and authenticated by assessment of cell morphology as well as STR fingerprinting. Mpan96 was used as an additional KRAS/MEK sensitive cell line based on prior literature. Subsequently, it was determined that this line is the same as ASPC1. We have verified this via STR fingerprinting. As we originally received the line as Mpan96, we elected to use this nomenclature when describing the line.

MiaPaCa2 clones resistant to AZD8330 were generated by two different methods: MiaPaCa2-R2 was cultured in 50 nM while MiaPaCa2-R2 was cultured immediately in 50 nM. 50 nM is needed to inhibit DHODH. On the other hand, Brequinar is a more potent and specific inhibitor of DHODH with proven efficacy when dosed in an intermittent pattern that allows periods of nucleotide depletion in a model of leukemia. Brequinar’s effects in vitro were more potent than leflunomide and it showed activity as a monotherapy in a xenograft model of human PDAC. Despite initial activity and even some complete responses, tumors ultimately progressed at a slower but sustained rate with BQ treatment. We showed that BQ-treated tumors didn’t upregulate other metabolic pathways and showed lower activation of proliferating markers. It remains to be evaluated the relevance of the effects observed on the tumor microenvironment, as well as developing effective combinatory therapeutic strategies. Furthermore, DHODH and RPIA inhibition was well tolerated in non transformed cells, suggesting that these pathways may have potential for therapeutic inhibition although more in vivo studies should be performed to conclusively determine this.

Overall, our work describes a differential metabolic rewiring in KRAS-resistant and sensitive cells, which is regulated by the MAPK-MYC-RPIA pathway. We identified nucleotide metabolism as a key mediator of KRAS resistance and we propose targeting enzymes in the PPP or the pyrimidine biosynthesis pathway to overcome resistance to MEK inhibitors and ultimately to future KRAS inhibitors that are in various stages of development.
glutamine concentration was adjusted to 25 mM and 4 mM, respectively, to keep consistent with DMEM. Alternatively, DMEM was supplemented with individual nucleosides (1 mM): uridine (Sigma U3003), inosine (Sigma, I14125) or the combination of both, during the selection process.

**Cell proliferation assays.** Cells were plated in 24-well plates at 3000–5000 cells per well. The day after plating, cells were treated with AZD8330, trametinib, letrozole or brequinar. Media was not refreshed for the duration of the assay. Cells were fixed in 10% formalin at the indicated time points and stained with 0.1% crystal violet. Colonies were counted and the surviving fraction was normalized to 0.5 after 48 h. The clonogenic survival assay was performed using the Clonogenic Survival Kit (Lonza). Cells were plated in the same setting as the combination of both, during the selection process.

**Clonogenic survival assay.** Cells were plated in 6 cm plates at 500 cells per dish. The day after plating, drugs were added at the indicated concentrations. In case of nucleotide rescue, these were maintained in the media for the course of the experiment since selection. After 7 days, cells were trypsinized and resuspended in their own media. Trypan blue (ThermoFisher) exclusion was measured using Cell-Titer Glo (Promega G7572) assay. Luminescence was normalized to 80% media.

**Cell death assays.** Trypan-blue exclusion. shKras and shRIPK1 cells were plated in 6-well plates at 50% confluency with or without nucleosides. 48 h after plating, cells were trypsinized and resuspended in their own media. Trypan blue (Thermo-scientific 15250861) positive cells were counted on a haematocytometer and percentage of cell death was normalized to shRIPK1 cells. Flow cytometry analysis of apoptosis. Cells were sorted and trypsinized after 48 h, as described. Cells were stained with Annexin-FITC and propidium iodide (PI) for 15 min (BD Biosciences 556547) using manufacturer’s protocol. Cells were placed in ice and analyzed using a Beckman Coulter Cytoflex.

**Lentivirus-Mediated shRNAs.** All shRNA vectors were obtained from the RNA Interference Screening Facility of Dana-Farber Cancer Institute unless indicated. The target sequences and/or RNAi Consortium clone IDs for each shRNA are as described. For AZD8330 treatment, 7000 cells were plated in 100 µl of media. 6 h after plating, AZD8330 was added to a final concentration of 50 nM and left for 72 h. For 24 h treatment, drug was added the day before measuring. In all cases, the day of media change, media was replaced with reconstituted DMEM (25 mM glucose, 4 mM glutamine, no sodium bicarbonate and pH adjusted to 7.4) and compounds were added at 37 °C for 30 min in a CO2-free incubator. Mitochondrial stress test was performed as described elsewhere. OCR and ECAR were normalized to cell number as determined by crystal violet at the end of the experiment. For glucose uptake and lactate production measurement, cells were seeded in 12-well plates in triplicate for 48 h. Glucose and lactate concentrations were measured in spent and fresh medium using a Yellow Springs Instruments (YSI) 2900. Glucose data is presented as net decrease in concentration, and lactate as net increase in concentration after normalization to cell number. Relative PPP arm activity was performed as described elsewhere.

**Metabolism studies.** OCR and ECAR measurements were performed using an XF-96 Instrument (Seahorse Biosciences). For shKras cells, 20,000 cells were plated in quadruplicate the day before and in wells were performed 24 h after plating. For AZD8330 treatment, 7000 cells were plated in 100 µl of media. 6 h after plating, AZD8330 was added to a final concentration of 50 nM and left for 72 h. For 24 h treatment, drug was added the day before measuring. In all cases, the day of media change, media was replaced with reconstituted DMEM (25 mM glucose, 4 mM glutamine, no sodium bicarbonate and pH adjusted to 7.4) and compounds were added at 37 °C for 30 min in a CO2-free incubator. Mitochondrial stress test was performed as described elsewhere. OCR and ECAR were normalized to cell number as determined by crystal violet at the end of the experiment. For glucose uptake and lactate production measurement, cells were seeded in 12-well plates in triplicate for 48 h. Glucose and lactate concentrations were measured in spent and fresh medium using a Yellow Springs Instruments (YSI) 2900. Glucose data is presented as net decrease in concentration, and lactate as net increase in concentration after normalization to cell number. Relative PPP arm activity was performed as described elsewhere.

**Metabolomics.** Steady state metabolomics experiments were performed as previously described. Briefly, shKras cells were plated in 6 cm plates in biological triplicate (DMEM, 25 mM glucose, 4 mM glutamine, 10% FBS). Media was changed two hours before metabolite collection. For AZD8330 treatment, cells were plated and media was refreshed the next day with drug/DMSO. Metabolite collection was performed 24 or 72 h after drug addition. Experiments were performed with 5 nM glucose/4 mM glutamine and 10 mM glucose/2 mM glutamine. For N15-Glutamine tracing experiments, cells were plated as described and pre-treated for 4 h with AZD8330 (50 nM) in 10 mM gc/2 mM glutamine DMEM. After that, media was refreshed to stable isotope-labeled glutamine (Amide-15N) DMEM containing 10% dialysed FBS and 10 mM glucose for 20 h. Media was refreshed 2 h before metabolite collection with media containing the labeled metabolite and drug, as described. Metabolite fractions were normalized to cell number obtained in a parallel 6 cm plate. 13C-isotope-labeled glucose (13 C) tracing experiments were performed as described elsewhere. For tissue metabolomics, metabolite fractions were normalized to tissue weight.

**Xenographs.** Xenograft studies were performed as described previously. Briefly, 2 x 105 Panc-1 cells were injected in the flanks of nude female mice (Taconic Bioscience). Once tumors reached 6–7 mm in diameter, under Dana Farber Cancer Institute IACUC protocol 10f, 6 weeks, 10 mice per group) under Dana-Farber Cancer Institute IACUC protocol 10f, 6 weeks, 10 mice per group. The second investigator performed the tumor measurements blinded to treatment groups. Mice were separated into two groups matched for tumor volume. Treatment was initiated when the total volume per group was 200 mm3. The group to receive the treatment vs. control was randomly determined. Brequinar was dissolved in 70% PBS x 1:30% PEG-400 and pH was adjusted to 7.00 with NaOH. Mice were injected once every other day for 4 days at 50 mg/kg with PQ or vehicle. For toxicity experiments, mice were injected for two weeks and at endpoint, blood was analyzed using an Advia 2100.

**Histology.** Tumors were processed as previously described. Antibodies used for immunostaining are as follows: Cleave caspase-3 (D175) (Cell Signaling Technology 9661; 1:500), Ki67 (Abcam Ab15580; 1:400), α-SMA (Dako, M0851, 1:500). Sections from 9 (vehicle) and 8 tumors (treatment group) were examined.
Chemicals. 11N-labelled glutamine (Cambridge Isotope Laboratories NLM-557-0.5), D-glucose (Sigma G7528), L-glutamine (Sigma G3126), AZD8330 (Selleckchem, S2134), trametinib (Selleckchem, S2673), GDC0941 (Selleckchem, S1065), lefunomide (Sigma L-5025), brequinor sodium salt (Sigma, SML013), uridine (Sigma, U3003), inosine (Sigma, I4125), mitochondrial stress kit (Seahorse 101706-100), VECTASTAIN Elite ABC Kit (pk-6100; Vector Labs), DAB (sk-4100; Vector labs).

Statistical analysis. Statistical analysis was done using GraphPad PRISM software. No statistical methods were used to predetermined sample size. For comparisons between two groups, Student’s t-test (unpaired, 2-tailed) was performed. Groups were considered different when p < 0.05.

Data availability
The authors declare that all the data supporting the findings of this study are available within the article and its Supplementary Information files and from the corresponding author upon reasonable request.

Received: 23 March 2018 Accepted: 1 November 2018
Published online: 23 November 2018

References
1. Rahib, L. et al. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913–2921 (2014).
2. National Cancer Institute. M. SEER Cancer Statistics Factsheets: Pancreas Cancer. (National Cancer Institute, Bethesda, 2012).
3. Ghané, P., Costello, E. & Neoptolemos, J. P. Biology and management of M. Cancer 61, 390–398 (2015).
4. Hidalgo, M. Pancreatic Cancer. N. Engl. J. Med. 368, 2055–2063 (2013).
5. Ryan, D. P., Hong, T. S. & Bardeesy, N. Pancreatic Adenocarcinoma. N. Engl. J. Med. 368, 2055–2063 (2013).
6. Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-activated mitogen-activated protein kinase pathway. Cancer Res. 71, 3546–3556 (2011).
7. Sakhnovich, S. A. et al. Oncomodulin: mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 59, 841–849 (2000).
8. Munier-Lehmann, H., Vidalain, P. O., Tangy, F. & Janin, Y. L. On dihydorootarate dehydrogenases and their inhibitors and uses. J. Med. Chem. 56, 3148–3164 (2013).
9. Sykes, B. D. et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell 167, 171–186 (2016).
10. Peters, G. J., Kral, I. & Pinedol, H. M. In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine. Br. J. Cancer 65, 229–233 (1992).
11. Yang, S. et al. Pancreatic cancers require autophagy for tumor growth. Cancer Res. 73, 693–703 (2013).
12. Patra, K. C. & Hay, N. The pentose phosphate pathway and cancer. Trends Biochem. Sci. 39, 347–354 (2014).
13. Alagesan, B. et al. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin. Cancer Res. 21, 396–405 (2015).
14. Kapoor, A. et al. Yap1 activation enables bypass of oncogenic KRAS addiction in pancreatic cancer. Cell 158, 185–197 (2014).
15. Martin, T. D. et al. A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells. Cell Rep. 20, 427–438 (2017).
16. Viale, A. et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial dysfunction. Nature 514, 628–632 (2014).
17. Breedveld, F. C. & Dayer, J. M. Leflunomide role of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 59, 841–849 (2000).
18. Ying, H. et al. Oncogenic Kras Maintains Pancreatic Tumors–A Transcriptional Program that Stimulates Hepatocarcinogenesis via PPP2A and ERK signaling. Int. J. Cancer 137, 104–115 (2015).
19. Hsu, J. et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat. Biotechnol. 31, 522–529 (2013).
20. White, R. M. et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 471, 518–522 (2011).
21. Brown, K. K., Spinelli, J. B., Asara, J. M. & Toker, A. Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. 7, 391–397 (2017).
22. Mathur, D. et al. PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydorootarate Dehydrogenase Inhibition. Cancer Discov. 7, 391–401 (2017).
23. Fragoso, Y. D. & Bidin Brooks, J. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev. Clin. Pharmacol. 8, 315–320 (2015).
24. Liu, N., Furukawa, T. & Kobari, M. Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Human Pancreas and Pancreatic Carcinoma. Am. J. Pathol. 149, 1878–1878 (2000).
25. Patra, K. C. & Hay, N. The pentose phosphate pathway and cancer. Trends Biochem. Sci. 39, 347–354 (2014).
26. Alagesan, B. et al. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin. Cancer Res. 21, 396–405 (2015).
27. Fang, J. et al. Dihydorootarate dehydrogenase is physically associated with the respiratory complex and its loss leads to mitochondrial dysfunction. Biochim. Biophys. Acta 3, 217–227 (2013).
28. Martin, T. D. et al. A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells. Cell Rep. 20, 427–438 (2017).
29. Viale, A. et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial dysfunction. Nature 514, 628–632 (2014).
30. Breedveld, F. C. & Dayer, J. M. Leflunomide role of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 59, 841–849 (2000).
31. Munier-Lehmann, H., Vidalain, P. O., Tangy, F. & Janin, Y. L. On dihydorootarate dehydrogenases and their inhibitors and uses. J. Med. Chem. 56, 3148–3164 (2013).
32. Sykes, B. D. et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell 167, 171–186 (2016).
33. Peters, G. J., Kral, I. & Pinedol, H. M. In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine. Br. J. Cancer 65, 229–233 (1992).
34. Daemen, A. et al. Metabolite profiling stratifies pancreatic ductal adenocarcinoma into subtypes with distinct sensitivities to metabolic inhibitors. PNAS 112, E4410–E4417 (2015).
35. Shukla, S. K. et al. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gempticatidine Resistance to Pancreatic Cancer. Cancer Cell. 32, 71–87 (2017).
36. Liu, N., Furukawa, T. & Kobari, M. Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Human Pancreas and Pancreatic Carcinoma. Am. J. Pathol. 149, 1878–1878 (2000).
37. Mathur, D. et al. PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydorootarate Dehydrogenase Inhibition. Cancer Discov. 7, 391–401 (2017).
38. Fragoso, Y. D. & Bidin Brooks, J. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev. Clin. Pharmacol. 8, 315–320 (2015).
39. Liu, N., Furukawa, T. & Kobari, M. Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Human Pancreas and Pancreatic Carcinoma. Am. J. Pathol. 153, 263–269 (1998).
40. Ouyang, H. et al. Immortal Human Pancreatic Duct Epithelial Cell Lines with Near Normal Genotype and Phenotype. Am. J. Pathol. 157, 1623–1631 (2000).
41. Kwak, H. et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68, 918–926 (68DA) (2008).
42. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).
supervised the metabolomics experiments as a core service. R.T.B interpreted slides and graded tumors according to intensity of staining. O.M. and C.A.L. performed and analyzed the metabolomics experiments for the Kras escaper cell line, respectively. H.Y. generated the Kras escaper cell lines and performed the associated metabolic studies. N.S. C. and A.C.K. analyzed the data and wrote the manuscript.

**Additional information**

**Supplementary Information** accompanies this paper at [https://doi.org/10.1038/s41467-018-07472-8](https://doi.org/10.1038/s41467-018-07472-8).

**Competing interests:** A.C.K. has financial interests in Vescor Therapeutics, LLC. A.C.K. is an inventor on patents pertaining to KRAS regulated metabolic pathways, redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach, and the autophagic control of iron metabolism. A.C.K. is on the SAB of Cornerstone/Rafael Pharmaceuticals.

**Reprints and permission** information is available online at [http://npg.nature.com/reprintsandpermissions/](http://npg.nature.com/reprintsandpermissions/)

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.